Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution Dates: shares and ADRs in Accustem

2 Jul 2021 12:30

RNS Number : 0370E
Tiziana Life Sciences PLC
02 July 2021
 

Tiziana Life Sciences plc

Distribution Dates for shares and ADRs in Accustem Sciences Limited

London, New York, 2 July 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the Forms 20-F and F-6 filed by Accustem Sciences Limited with the SEC have been declared effective, enabling the completion of the in specie distribution and spin out of Accustem Sciences Limited. These documents can be found at www.accustem.com

Times and dates for holders of Tiziana ordinary shares (traded on the London Stock Exchange)

The timetable for the holders of Tiziana ordinary shares (traded on the London Stock Exchange) held in CREST and Certificated form is as follows:

Demerger Record Time: 7:00 a.m. on 30 October 2020

Ex-entitlement date for Accustem Shares: 2 November 2020

CREST accounts credited with Accustem Shares: 8 July 2021*

Certificates for Accustem Shares for those shareholders

holding their Tiziana Life Sciences plc in certificated form: by 18 July 2021

* replacing allocation placeholders currently showing

Times and dates for holders of Tiziana ADSs (traded on the US Nasdaq Market)

The timetable for the holders of Tiziana ADSs (traded on the Nasdaq market) are subject to different corporate action timings and holders of the ADRs should also refer to the notice published today by JP Morgan, the ADR depositary bank which can be found at https://www.adr.com/drprofile/88875G101

Announcement Tiziana CUSIP: 88875G101

Corporate Action Type: Spin Off with DR Distribution

Spin Off Issuer Name: Accustem Sciences Limited

Spin Off DR CUSIP: 00442Y101

DR Distribution Rate: 1 new Accustem DR(s) issued for every 1 existing Tiziana DR held on DR Record Date

Tax Withholding Rate: n/a

DR Record Date: November 6, 2020

DR Payment Date: July 14, 2021

DR Issuance and Cancellation Books close Date: October 28, 2020

DR Issuance and Cancellation Books reopen Date: July 19, 2021

Fees: Issuance fee: $nil per DR issued

The Issuer has announced a Spin Off Distribution in the local market. Existing Tiziana DRs will continue to be valid and will not have to be exchanged for new DRs.

For further enquiries:

United Kingdom:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

+44 (0)20 7495 2379

United States:

Investors:

Dave Gentry, CEO

RedChip Companies Inc.

1-800-RED-CHIP (733-2447)

or

407-491-4498

dave@redchip.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDZGGNGZNGMZM
Date   Source Headline
20th Oct 20212:29 pmRNSScheme of arrangement
20th Oct 20212:00 pmRNSPrice Monitoring Extension
20th Oct 20217:00 amRNSDirector/PDMR Shareholding
19th Oct 20212:01 pmRNSCapital Reorganisation
6th Oct 20213:19 pmRNSDirector/PDMR Shareholding
5th Oct 20217:00 amRNSDirector/PDMR Dealing
4th Oct 20218:06 amRNSPDMR Dealing
28th Sep 20217:00 amRNSDirector/PDMR Shareholding
27th Sep 20215:16 pmRNSResult of Meeting
27th Sep 20215:11 pmRNSResult of Meeting
24th Sep 20215:49 pmRNSHalf-year Report
20th Sep 202111:05 amRNSSecond Price Monitoring Extn
20th Sep 202111:00 amRNSPrice Monitoring Extension
20th Sep 20219:05 amRNSSecond Price Monitoring Extn
20th Sep 20219:00 amRNSPrice Monitoring Extension
7th Sep 20216:00 pmRNSChange of Registered Office
7th Sep 20217:00 amRNSTLSA to Host Call to Discuss Exclusive License
3rd Sep 20215:00 pmRNSPosting of Scheme Document and Notice of Meetings
3rd Sep 20217:00 amRNSPosting of Scheme Document and Notice of Meetings
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:00 amRNSPrice Monitoring Extension
2nd Sep 20217:00 amRNSLicense Agreement to Evaluate Foralumab with CAR T
20th Aug 20217:00 amRNSTiLS files scheme for a corporate reorganisation
17th Aug 20217:00 amRNSArticle Publication on Foralumab in COVID Patients
16th Aug 20216:11 pmRNSTLSA to Present at the Q3 Virtual Investor Summit
3rd Aug 20214:41 pmRNSSecond Price Monitoring Extn
3rd Aug 20214:35 pmRNSPrice Monitoring Extension
8th Jul 202112:19 pmRNSADS Ex-Dividend Date Scheduled for July, 09 2021
2nd Jul 202112:30 pmRNSDistribution Dates for shares and ADRs in Accustem
2nd Jul 202112:30 pmRNSDistribution Dates: shares and ADRs in Accustem
30th Jun 202111:36 amRNSDr Howard Weiner on Bloomberg at 1.50pm ET today
25th Jun 202110:40 amRNSResult of Annual General Meeting
23rd Jun 20217:00 amRNSP2 Trial with foralumab on Severe COVID19 Patients
21st Jun 20217:08 amRNSAppointment of VP of Regulatory Affairs
17th Jun 20217:00 amRNSTiziana Applies for Grant from UK-CTAP
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20217:00 amRNSSignificant Immunomodulation effects on Biomarkers
25th May 20217:00 amRNSTrial Initiation in a SPMS Patient with Foralumab
21st May 20217:00 amRNSDirector/PDMR Dealing
18th May 202112:18 pmRNSAmended - Final Results
18th May 202111:08 amRNSFinal Results
7th May 20217:00 amRNSTLSA interview on Bloomberg TV on 8th May 2021
5th May 20217:45 amRNSTLSA Strategic Initiative with Takanawa Japan K.K.
27th Apr 20217:00 amRNSB. Riley Virtual Neuroscience Investor Conference
13th Apr 202112:00 pmRNSTiziana Announces Plans to List Accustem in US
30th Mar 20214:41 pmRNSSecond Price Monitoring Extn
30th Mar 20214:36 pmRNSPrice Monitoring Extension
30th Mar 20212:05 pmRNSSecond Price Monitoring Extn
30th Mar 20212:00 pmRNSPrice Monitoring Extension
30th Mar 20211:00 pmRNSFDA Allows Foralumab Treatment for a SPMS Patient

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.